Pharming Group N.V. announces it will host a webcast for investors and analysts featuring Joshua Milner, MD, an internationally renowned immunologist, to discuss the findings of a recent study published in the peer-reviewed journal Cell.

The study titled “Scalable generation and functional classification of genetic variants in inborn errors of immunity for improved clinical diagnosis and management” was led by Zachary Walsh, MD/PhD candidate, Dr. Milner and Benjamin Izar, MD, PhD of Columbia University. The publication details significant advances in diagnosing inborn errors of immunity, also known as primary immune disorders. The researchers’ approach helps resolve a major limit to interpretation of genetic testing that often yields variants of uncertain significance (VUS) when evaluating such disorders, including activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

The webcast will take place on Monday, June 30, 2025, at 16:30 CEST / 10:30 EDT. 

To participate, please register at https://edge.media-server.com/mmc/p/q6x83at2. Questions can be submitted in advance, via email to investor@pharming.com. 

For more information and to access the full peer-reviewed study in Cell, please visit https://www.cell.com/cell/abstract/S0092-8674(25)00624-5.